DLK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15882483	1.00	3/20
SCHEMBL15882777	1.00	3/20
SCHEMBL15890043	1.00	3/20
SCHEMBL15889966	0.90	3/20
SCHEMBL15882678	0.84	3/20
SCHEMBL15890053	0.82	3/20
SCHEMBL15882748	0.82	3/20
SCHEMBL15882684	0.81	3/20
SCHEMBL15882480	0.79	3/20
SCHEMBL15882525	0.79	3/20
SCHEMBL15882739	0.77	3/20
SCHEMBL15882600	0.70	3/20
SCHEMBL15889989	0.69	3/20
SCHEMBL15890017	1.00	2/20
SCHEMBL15882733	0.87	2/20
SCHEMBL15320639	0.83	2/20
SCHEMBL15320643	0.83	2/20
SCHEMBL2133125	0.80	2/20
SCHEMBL8280372	0.79	2/20
SCHEMBL2205691	0.78	2/20

Clinical trials — most relevant to DLK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
NG2 and DLL3 CAR-T Cells Targeting Melanoma	PHASE1/PHASE2	RECRUITING
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis	PHASE2	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer	PHASE1/PHASE2	COMPLETED
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	PHASE2	COMPLETED
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors	PHASE1	RECRUITING
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma	PHASE1	COMPLETED
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients	PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
New Signaling Pathway Targeting Systemic Lupus Erythematosus	nan	UNKNOWN
Emerging Role of NOTCH-related Long Non-coding RNA(s) as Biomarkers in Liquid Biopsy From Colorectal Cancer Patients	nan	COMPLETED
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury	nan	UNKNOWN
DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma	nan	COMPLETED
DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia	nan	COMPLETED
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science	nan	RECRUITING
Genetic Variants of Selected Genes in Colo-Rectal Cancer Patients.	nan	UNKNOWN
Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC)	nan	UNKNOWN
Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients	nan	NOT_YET_RECRUITING
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
The Activation of Hippo Pathway in Nasal Polyps	nan	UNKNOWN
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia	nan	UNKNOWN
Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs	nan	COMPLETED
Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma	nan	UNKNOWN
Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia	nan	UNKNOWN
IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a DLK1 binder may also engage these)

Protein	Name	Similarity
O70534	—	1.000	O70534 →
Q09163	—	1.000	Q09163 →
Q9WUA1	—	0.987	Q9WUA1 →
Q6IN38	—	0.986	Q6IN38 →
Q8K1E3	—	0.986	Q8K1E3 →
Q9W7R4	—	0.986	Q9W7R4 →
Q9Y5W5	—	0.986	Q9Y5W5 →
Q9W6F9	—	0.984	Q9W6F9 →
P15306	—	0.984	P15306 →
Q9JJS0	—	0.982	Q9JJS0 →
B2LW77	—	0.982	B2LW77 →
Q9NQ36	—	0.982	Q9NQ36 →
Q9ET61	—	0.981	Q9ET61 →
Q61592	—	0.981	Q61592 →
Q8IWY4	—	0.981	Q8IWY4 →
Q9UKZ4	—	0.981	Q9UKZ4 →
Q9W6F8	—	0.981	Q9W6F8 →
DNER	Delta and Notch-like epidermal growth factor-related receptor	0.980	landscape →
Q61521	—	0.980	Q61521 →
Q61483	—	0.980	Q61483 →
Q7T3Q2	—	0.979	Q7T3Q2 →
Q53RD9	—	0.979	Q53RD9 →
O00548	—	0.979	O00548 →
P78504	—	0.979	P78504 →
A4FV93	—	0.979	A4FV93 →
Q9NR61	—	0.979	Q9NR61 →
Q9WTS4	—	0.979	Q9WTS4 →
P35952	—	0.979	P35952 →
Q9NZV1	—	0.979	Q9NZV1 →
Q63772	—	0.979	Q63772 →